Qlife Holding AB (publ) (QLIFE.ST)
SEK 2.1
(5.53%)
SEK 2.1
(5.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -168.69 Million SEK | -63.62% |
| 2022 | -95.73 Million SEK | -74.5% |
| 2021 | -54.86 Million SEK | -75.15% |
| 2020 | -31.32 Million SEK | -522.62% |
| 2019 | -5.03 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.01 Million SEK | 36.12% |
| 2024 Q1 | -12.53 Million SEK | 87.95% |
| 2023 FY | -156.64 Million SEK | -63.62% |
| 2023 Q3 | -11.99 Million SEK | 47.3% |
| 2023 Q4 | -104.03 Million SEK | -767.58% |
| 2023 Q1 | -17.86 Million SEK | 47.88% |
| 2023 Q2 | -22.75 Million SEK | -27.37% |
| 2022 Q3 | -18.56 Million SEK | 21.85% |
| 2022 Q2 | -23.75 Million SEK | -24.4% |
| 2022 Q1 | -19.09 Million SEK | -10.92% |
| 2022 FY | -95.73 Million SEK | -74.5% |
| 2022 Q4 | -34.27 Million SEK | -84.65% |
| 2021 Q1 | -7.72 Million SEK | 20.81% |
| 2021 FY | -54.86 Million SEK | -75.15% |
| 2021 Q4 | -17.21 Million SEK | -0.26% |
| 2021 Q3 | -17.17 Million SEK | -33.9% |
| 2021 Q2 | -12.82 Million SEK | -66.01% |
| 2020 FY | -31.32 Million SEK | -522.62% |
| 2020 Q4 | -9.75 Million SEK | -24.06% |
| 2020 Q3 | -7.86 Million SEK | -57.48% |
| 2020 Q2 | -4.99 Million SEK | 41.34% |
| 2020 Q1 | -8.51 Million SEK | 63.01% |
| 2019 Q3 | -2.65 Million SEK | -8.11% |
| 2019 FY | -5.03 Million SEK | 0.0% |
| 2019 Q1 | -1.9 Million SEK | 0.0% |
| 2019 Q2 | -2.45 Million SEK | -28.82% |
| 2019 Q4 | -23.01 Million SEK | -767.43% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | -117.525% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 156.12% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 156.12% |
| Arcoma AB | 4.66 Million SEK | 3720.107% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | -27.866% |
| BICO Group AB (publ) | -618.3 Million SEK | 72.716% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 529.582% |
| CellaVision AB (publ) | 167.05 Million SEK | 200.985% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | -155.861% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -470.47% |
| C-Rad AB (publ) | 44.24 Million SEK | 481.288% |
| Duearity AB (publ) | -25.76 Million SEK | -554.803% |
| Dignitana AB (publ) | -15.02 Million SEK | -1022.701% |
| Episurf Medical AB (publ) | -94.8 Million SEK | -77.95% |
| Getinge AB (publ) | 3.81 Billion SEK | 104.423% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | -146.468% |
| Iconovo AB (publ) | -45.77 Million SEK | -268.521% |
| Integrum AB (publ) | 6.51 Million SEK | 2690.421% |
| Luxbright AB (publ) | -25.8 Million SEK | -553.752% |
| Mentice AB (publ) | -679 Thousand SEK | -24744.919% |
| OssDsign AB (publ) | -91.95 Million SEK | -83.454% |
| Paxman AB (publ) | 12.61 Million SEK | 1436.849% |
| Promimic AB (publ) | -9.11 Million SEK | -1750.154% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -212.755% |
| ScandiDos AB (publ) | -13.48 Million SEK | -1151.183% |
| Sectra AB (publ) | 518.49 Million SEK | 132.536% |
| Sedana Medical AB (publ) | -65.54 Million SEK | -157.368% |
| Senzime AB (publ) | -133.74 Million SEK | -26.133% |
| SpectraCure AB (publ) | -21.35 Million SEK | -690.113% |
| Stille AB | 44.95 Million SEK | 475.283% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 95.3% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 538.106% |